RxDoctor Payments Data

Robert Wansley

Primary Care · Laurel, MSNPI 1821320201

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Novo Nordisk at 43.0% of the total. Reporting peaked in 2024 at $71 and has fallen 51.4% since, to $34 in 2025. That places this record below the midpoint for primary care clinicians in MS, where the typical reported total is $380.

$219in general payments, 2019–2025

Across 14 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$94
  • Lilly USA, LLC$36
  • Boehringer Ingelheim$35
  • AbbVie$27
  • Medtronic$16
  • Pfizer$11

What the payments were for

  • Food & beverage$219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$219 in reported general payments places this provider in the 30th percentile of 80 primary care providers in Mississippi.

See all primary care providers in Mississippi

Medicare billing

Part B allowed, 2024
$159,543
Medicare patients
350
Services billed
4,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$104,001
OzempicSemaglutide70$72,438
JardianceEmpagliflozin35$37,329
Tresiba Flextouch U-200Insulin Degludec19$36,594
JanuviaSitagliptin Phosphate29$33,453
EliquisApixaban18$17,549
LinzessLinaclotide17$16,287
TrulicityDulaglutide14$15,542
QuliptaAtogepant11$13,966
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,185
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$11,998
Breo ElliptaFluticasone/Vilanterol17$6,477
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$6,131
SymbicortBudesonide/Formoterol Fumarate23$5,526
Levemir FlexpenInsulin Detemir12$5,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$36$119,543102 claims
Novo NordiskOzempic$94$72,43870 claims
Boehringer IngelheimJardiance$35$37,32935 claims
AbbVieLinzess, Qulipta, Synthroid$27$31,50646 claims
PfizerEliquis$11$17,54918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 80 primary care providers in Mississippi.

Other primary care in Laurel

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →